Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RAPT vs TWST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RAPT Captures Overall Composite Edge (52.4 HOLD vs 51.7 HOLD), While TWST Leads 5–1 on Growth & Valuation Pillars

RAPT Overall Winner 6-Pillar Tally: RAPT 1 – 5 TWST Matrix Metrics: RAPT 5 – 3 TWST

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Twist Bioscience Corporation (TWST) on higher Unified Composite conviction (52.4/100 HOLD vs. 51.7/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while TWST wins 5–1 across the 6-pillar growth and valuation breakdown. RAPT trades at $58.02 (N/M Forward P/E, 0.0% operating margin) versus TWST at $105.61 (N/M Forward P/E, -31.9% operating margin).

  • Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. TWST 51.7/100 HOLD) and -0.02β · 2% Vol risk profile, whereas TWST leads top-line expansion (+23.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RAPT vs TWST
RAPT NASDAQ Head-to-Head Winner
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67
TWST NASDAQ
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.61
-5.37% 1D
Market Cap $7.6B
TTM Revenue $432M
Forward P/E N/M
Beta / 30D Vol 3.13β · 126% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 36.1 · SMA20: $137.35 · SMA50: $149.85

6-Pillar Scorecard Institutional Category Breakdown (RAPT 1 – 5 TWST)

Columns: Metric · RAPT · TWST
1. Valuation Multiples TWST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 17.5x
2. Growth & Scale TWST
Revenue Growth (YoY) -100.0% +23.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $432M
Market Cap $1.7B $7.6B
3. Profitability & Quality RAPT
Gross Margin N/A 52.0%
Operating Margin 0.0% -31.9%
Net Profit Margin 0.0% -31.7%
Return on Equity (ROE) -85.4% -29.6%
4. Balance Sheet & Cash Flow TWST
Cash Generation (TTM) N/A -$115M EBITDA
Cash Flow Margin N/A -26.7% EBITDA Mgn
Net Cash / Leverage $9.02 Book/Sh · -85.4% ROE $7.11 Book/Sh · -29.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TWST
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 0.8% (<1st %ile) 93.2% (18th %ile)
Put/Call OI Skew N/A 1.04x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity N/A 83.9% of Rev ($362M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RAPT (5) vs TWST (3)
Institutional Metric RAPT TWST Criterion Row Edge
Market Capitalization
Scale
$1.7B $7.6B Larger Scale TWST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +23.2% Higher Growth TWST
Operating Margin (TTM)
Profitability
0.0% -31.9% Higher Margin RAPT
Net Profit Margin
Profitability
0.0% -31.7% Higher Margin RAPT
Return on Equity (ROE)
Capital Efficiency
-85.4% -29.6% Higher ROE TWST
52-Week Range Position
Momentum
100% ($1–$58) 42% ($23–$220) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
-0.02β · 2% Vol 3.13β · 126% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
52.4 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
N/A $432M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 52.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 17.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($9.02 Book/Sh · -85.4% ROE) -$115M EBITDA ($7.11 Book/Sh · -29.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TWST +9.69 pp
RAPT: +0.68% · TWST: +10.37%
3M Horizon RAPT +29.68 pp
RAPT: +74.44% · TWST: +44.76%
6M Horizon RAPT +31.16 pp
RAPT: +101.95% · TWST: +70.79%
1Y Horizon RAPT +31.16 pp
RAPT: +101.95% · TWST: +70.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs TWST. Trailing 12-month operating profitability (RAPT 0.0% vs TWST -31.9%) and valuation multiples (RAPT N/M vs TWST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M
TWST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$432M
Gross Margin52.0%
Op. Margin-31.9%
ROE / Fwd P/E-29.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 93.2%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.6B market capitalization and -31.9% operating margin.
OpEx & R&D Reinvestment 83.9% of Rev ($362M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ RAPT vs TWST Key Questions & Quantitative Answers

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Twist Bioscience Corporation (TWST) on higher Unified Composite conviction (52.4/100 HOLD vs. 51.7/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while TWST wins 5–1 across the 6-pillar growth and valuation breakdown. RAPT trades at $58.02 (N/M Forward P/E, 0.0% operating margin) versus TWST at $105.61 (N/M Forward P/E, -31.9% operating margin). Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. TWST 51.7/100 HOLD) and -0.02β · 2% Vol risk profile, whereas TWST leads top-line expansion (+23.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

TWST leads the Growth & Scale pillar: RAPT posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TWST at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $432M TTM revenue (52.0% gross margin, -31.9% operating margin). On trailing 12-month operating scale, RAPT generates N/A in USD-normalized revenue versus $432M for TWST. In operating R&D and SG&A reinvestment, RAPT deploys N/A (0 90-day corporate R&D disclosures) versus 83.9% of Rev ($362M) (0 disclosures) for TWST.

TWST screens cheaper on headline valuation multiples. RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.5x EV/Revenue (-26.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPT (-85.4% ROE) versus TWST (-29.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk). By comparison, TWST carries 93.2% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.